Prevention and Management of Heart Failure – Stage A/B Framework from Japan Heart Failure Society (JHFS)
The 2025 JHFS Scientific Statement on Heart Failure Prevention - Stage A/B Diagnosis and Treatment Flowchart provides a pragmatic, evidence-based roadmap for recognizing and managing these early disease stages.
Related Links
- Integrating CGM Data to Uncover Nocturnal Patterns
- Physiology and Epidemiology of Sleep Disruptions in Diabetes
- Turning Routine Data to Predictive Care: Dr. Navdeep Tangri on CKD Risk Stratification using Algorithms
- NT-proBNP for Cardiovascular Risk Stratification in T2DM: From Evidence to Clinical Practice
- Perioperative Myocardial Injury (PMI): How to Build and Implement a Successful Multidisciplinary Team Protocol
- Beyond HbA1C: Overcoming Challenges in Insulin-Treated Type 2 Diabetes
- APSC Consensus Statement on the Management of Worsening Heart Failure
- Navigating Cardiotoxicity: A Practical Guide to Cardiac Biomarkers during Chemotherapy
- Continuous Glucose Monitoring with AI-enabled Predictive Algorithms for Diabetes Care: Expert Views from Hong Kong
- Optimising Perioperative Outcomes: A Practical Guide to Cardiac Biomarkers in Noncardiac Surgery
- ACC 2025 Spotlight: DROP-Asian ACS Interim Analysis Highlights Regional Gains in NSTEMI Care
- Empowering the Everyday: AI-enabled CGM Is the Next Leap in Diabetes Care
- Lipoprotein(a) in clinical practice
- STRONG-HF Japan Study
- Innovative Strategies to Optimise Heart Failure GDMT at Prince Wales Hospital’s Heart Failure Clinic
- STRONG-HF Recommended in Updated China National Heart Failure Guideline 2023
- Rapid Titration (RaT) Pathway For Optimising Heart Failure GDMT with comprising several hospitals in Northland
- Reducing Mortality and Readmission with HF Multidisciplinary Model of Care
- Culturally Sensitive Diabetes Care
- What Causes Falsely High & Low HbA1c Reading?
- Menopause and Diabetes
- Screening for Occult Heart Failure (HF) in Type 2 Diabetes Mellitus (T2DM) using NT-proBNP
- Value of biomarker in HFpEF Diagnosis
- Sex-specific Differences in Heart Failure
- Management of CVD in Patients with Diabetes
- Heart Failure Care Beyond City Limits: Insights from a Cardiologist
- Implementation of STRONG-HF protocol in heart failure management: an Australian perspective
- When every minute counts: A deep dive into IJN Malaysia’s quest for rapid triage for chest pain patients in the ED
- Quantum leap in reducing rehospitalization in HF by 70-80% – How and where?
- Heart failure management in Australia and the role of NT-proBNP in monitoring and treatment
- Perioperative myocardial injury (PMI) management: Challenges and feasibility of active screening in non-cardiac surgeries
- Heart Failure Management in India – Overcoming Present Challenges
- Rational use of troponin and optimal management of cardiovascular diseases</strong>
- The evidence for 0/1-hour algorithm for Asia? DROP-Asian ACS Study
- Process Optimization for Emergency hs-TnT Detection
- Clinical Application NT-proBNP in CKD (Chronic Kidney Diseases) Patients with Cardiovascular Diseases
- High Sensitivity Troponin vs Conventional Troponin: An Expert View
- The rationale for the use of hs-cTn in the optimal management of ACS
- Rapid algorithms for hs-cTn in ED: Boon or Bane?
- STROKESTOP II Study: Precision risk screening for atrial fibrillation in elderly
- Atrial Fibrillation in Elderly: Screening tools and role of NT-proBNP
- Advantages of early NT-proBNP testing in patients suspected with heart failure
- NT-proBNP: Increasing Clinical Confidence in Heart Failure Management
- What is the Peptide for Life initiative?
- Heart Failure in Asia – Present Challenges and Future Strategies
- Perioperative Myocardial Infarction in Non-Cardiac Surgery – Why Measuring Troponin is Important?
- Heart Failure Prevention in T2DM – Essence of JCS/JDS joint consensus
- CANVAS (CANagliflozin cardioVascular Assessment Study): NT-proBNP and CVD risk reduction
- What should we take note of when using hs-TnT for CKD patient?
- Clinical Relevance – High-Sensitivity Troponin Results Influenced by Age
- Clinical Relevance of hs-TnT gender specific cut-offs
- Recommended Steps to Implement 0h/1h Algorithm in Asia
- Benefits of 0h/1h Algorithm in a Thai Institution
- Benefits of 0h/1h Algorithm to Patients in Asia
- How will NT-proBNP testing evolve in the future?
- Is NT-proBNP validated for different population groups?
- Reference ranges for NT-proBNP & hs-TnT in Asian populations
- Benefits of the 0h/1h algorithm in a Japanese institution
- Patient Case Studies Using 0h/1h Algorithm
- BNP vs NT-proBNP: An Expert View
- Impact of ARNi Therapy on Natriuretic Peptide Use
- How to Use NT-proBNP for Prognosis and Monitoring?
- What Should Hospitals Consider when Implementing Rapid Algorithm?
- TRAPID-AMI sub-study: Use of very low concentration of hs-TnT to rule out AMI using a single blood test
- Benefits of hs-Tn 0h/1h Algorithm in ED & Hospital
- TRAPID-AMI Study: hs-TnT for Rapid Rule In/ Out of AMI
- Benefits of hs-Tn 0h/1h Algorithm to Chest Pain Patients
- How NT-proBNP Made a Difference: Dr Januzzi’s Patient Story
- Impact of High-Sensitivity Cardiac Troponin (hs-Tn) on Further Cardiac Testing in Suspected AMI Patients
- Advantages of Switching from Conventional to High-Sensitivity Troponin
- How hs-TnT Made a Difference – Dr Twerenbold’s Story
- How NT-proBNP Made a Difference: Dr Richards’ Patient Story
- Natriuretic Peptides in the Latest ESC & AHA HF Guidelines
- Role of Natriuretic Peptides in Patients with Dypsnea